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Abstract
Aims The aim of this study was to compare long-term safety and efficacy of the basal insulin analogue degludec with
glargine in insulin-naive subjects with Type 2 diabetes.
Methods This open-label trial included a 52-week core period followed by a 52-week extension. Participants were
randomized 3:1 to once-daily degludec or glargine, administered with metformin  dipeptidyl peptidase-4 inhibitors.
Basal insulin was titrated to target pre-breakfast plasma glucose 3.9–4.9 mmol/l.
Results At end of treatment (104 weeks), mean HbA1c reductions were similar for degludec and glargine; estimated
treatment difference between degludec and glargine was 1 mmol/mol (95% CI 1 to 3) [0.07% (95% CI 0.07 to 0.22)],
P = 0.339 in the extension trial set (degludec 551, glargine 174), comprising subjects who completed core trial and
continued into the extension trial. Overall confirmed hypoglycaemia rates (1.72 vs. 2.05 episodes/patient-year), rates of
adverse events possibly or probably related to trial product (0.19 events/patient-year), weight gain (2.7 vs. 2.4 kg) and
mean daily insulin doses (0.63 U/kg) were similar between treatments in the safety analysis set (degludec 766, glargine 257)
comprising all treated subjects. Rates of nocturnal confirmed hypoglycaemia (0.27 vs. 0.46 episodes/patient-year;
P = 0.002) and severe hypoglycaemia (0.006 vs. 0.021 episodes/patient-year, P = 0.023) were significantly lower with
degludec for the safety analysis set (analysis based on intention-to-treat full analysis set comprising all randomized subjects).
Conclusions In Type 2 diabetes, insulin degludec in combination with oral anti-diabetic drugs, safely and effectively
improves long-term glycaemic control, with a significantly lower risk of nocturnal hypoglycaemia as compared with
glargine.
Diabet. Med. 30, 1298–1304 (2013)
Introduction
Insulin degludec, a new basal insulin analogue with an
ultra-long duration of action [1], was compared with
glargine in a 52-week, randomized, treat-to-target study
(BEGIN Once Long) in insulin-naive participants with
Type 2 diabetes, inadequately controlled with oral anti-
diabetic drugs. Administration of degludec or glargine once
daily in combination with oral anti-diabetic drugs [with all
participants using metformin and < 2% using dipeptidyl
peptidase-4 (DPP-4) inhibitors at end of treatment] provided
similar improvements in glycaemic control, with a lower rate
of nocturnal hypoglycaemia with degludec [2]. The objective
of the extension study reported here was to compare the
long-term safety and tolerability of degludec with glargine
for 104 weeks of treatment.
Patients and methods
The BEGIN Once Long study design has been previously
described [2]. The core trial was a 52-week randomized,
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controlled, parallel-group, open-label, multinational,
treat-to-target, non-inferiority trial in which 1030 insu-
lin-naive patients with Type 2 diabetes, inadequately con-
trolled with oral anti-diabetic drugs, were randomly
assigned in a 3:1 ratio to treatment with once-daily insulin
degludec or once-daily insulin glargine, respectively. The
insulin was administered subcutaneously in combination
with metformin and a DPP-4 inhibitor (use of the latter
was dependent on country-specific approved labelling that
allowed combining the DPP-4 inhibitor with insulin).
Subjects who completed the 52-week core trial and
provided informed consent entered the 52-week extension
trial maintaining prior randomization. The extension trial
was conducted between 9 September 2010 and 20
December 2011 in accordance with the Declaration of
Helsinki [3] and Good Clinical Practice [4]. Protocols were
approved by independent ethics committees/institutional
review boards prior to the trials.
Insulin degludec was administered once daily with the
main evening meal and glargine was administered once daily
at the same time every day, as chosen by patient and
investigator, as per approved labelling. In the core trial, the
starting dose for both insulins was 10 Units. Basal insulin
was titrated to target pre-breakfast plasma glucose of
3.9–4.9 mmol/l based on the mean of pre-breakfast
self-monitored blood glucose values of the preceding two
or three consecutive days. The initial insulin dose in the
extension trial was to be the same as the dose at end of
treatment of the core trial, but could be adjusted at
investigator discretion.
To assess the immunogenicity of degludec and to minimize
interference with antibody measurements, a 1-week basal
insulin washout period was scheduled at end of treatment of
both the 52-week core trial and the extension period, during
which participants in both arms were switched to twice-daily
neutral protamine Hagedorn (NPH) insulin (with a 20%
reduction in total basal dose).
Safety and efficacy assessments in the extension trial were
as described previously for the core trial [2]. As the primary
objective of the extension trial was to investigate the
long-term safety and tolerability of insulin degludec, the
following safety variables were the primary endpoints in the
extension trial: adverse events (including injection-site reac-
tions), hypoglycaemia episodes, insulin dose, body weight,
clinical evaluations (including physical examination, vital
signs, fundoscopy, electrocardiogram) and central laboratory
tests (including insulin antibodies). Safety endpoints were
summarized and analysed using the safety analysis set
(comprising all subjects exposed to treatment). The statistical
analysis of hypoglycaemia episodes and weight change
observed in the safety analysis set was based on the full
analysis set (comprising all randomized subjects). Hypo-
glycaemia was also analysed in the extension trial set
(comprising completers of the core trial that continued into
the extension trial) for the entire trial period and (post hoc)
in the maintenance period (when the average insulin dose
had stabilized, i.e. from week 16 to the end of 104 weeks of
treatment). The number of hypoglycaemic episodes per
patient-year were analysed by use of a negative binomial
regression model that included treatment category, anteced-
ent anti-diabetic therapy at screening, sex and region as fixed
factors and age as covariate. However, severe hypoglycaemia
was analysed using a Poisson regression model, as the
negative binomial regression model could not be fitted to the
sparse data for severe hypoglycaemia.
Efficacy variables assessed in the core and extension trial
included HbA1c, central laboratory-measured fasting plasma
glucose, 9-point self-monitored blood glucose profile and a
questionnaire based on patient-reported outcomes. Treat-
ment differences in the efficacy variables and in body weight
were analysed using analysis of variance (ANOVA) with
treatment, anti-diabetic therapy at screening, sex and region
as fixed factors, and age and baseline value as covariates. In
addition to analysing glycaemic efficacy in the full analysis
set, the extension trial set was analysed for HbA1c and post
hoc for fasting plasma glucose and self-monitored blood
glucose. Baseline was defined as the time of randomization in
the core trial. Post-baseline missing values were imputed
using the last-observation-carried-forward method. Statisti-
cal analysis results include estimated mean treatment differ-
ences (or ratios) with their two-sided 95% confidence
intervals and P-values (post hoc) for two-sided testing with
an a (type I error probability) of 0.05.
Results
Of 773 participants randomized to degludec, 607 (79%)
completed the core (52-week) trial; of these, 551 (71%)
continued into the extension period and 505 (65%) com-
pleted the second year of study. Of 257 participants initially
What’s new?
• Insulin degludec, a basal insulin analogue, uses a novel
protraction mechanism, resulting in a flat, stable profile
and a duration of action greater than 42 h.
• Consistent with its pharmacokinetic and pharmacody-
namic profile, insulin degludec in combination with
oral anti-diabetic drugs provided long-term glycaemic
control similar to insulin glargine with a lower risk for
nocturnal hypoglycaemia in insulin-naive patients with
Type 2 diabetes, in a 1-year, randomized study.
• This extension study reports 2-year data, confirming
that insulin degludec in combination with oral anti-
diabetic drugs maintains stable glycaemic control with
a sustained benefit in reducing hypoglycaemic risk in
Type 2 diabetes.
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randomized to glargine, 197 (77%) completed the core trial;
174 (68%) of these continued into the extension period and
154 (60%) completed the 104-week trial. Participants were
withdrawn in the extension period from the degludec and
glargine groups because of adverse events [12 (1.6%) and five
(1.9%)], ineffective therapy [three and one (0.4% each)],
non-compliance [two (0.3%) and four (1.6%)], for meeting
withdrawal criteria [six (0.8%) and three (1.2%), see also
Supporting Information, Table S1] and ‘other’ reasons [23
(3.0%) and seven (2.7%)], with loss to follow-up being the
most common ‘other’ reason. Baseline characteristics of the
two treatment groups in the extension trial set were well
matched and similar to those of the full analysis set (see also
Supporting Information, Table S2).
Safety
In the safety analysis set, comprising subjects receiving
treatment (degludec 766, glargine 257), themean basal insulin
dose at end of treatment was identical: 0.63 ( 0.39) U/kg
for degludec and 0.63 ( 0.36) U/kg for glargine. Con-





FIGURE 1 Confirmed hypoglycaemia and glycaemic efficacy in the insulin degludec and glargine groups. (a) Overall confirmed hypoglycaemic
episodes. (b) Nocturnal confirmed hypoglycaemic episodes. (c) HbA1c vs. time. (d) Fasting plasma glucose vs. time. The green box in (c) and (d) on
the horizontal axes between weeks 52 and 53 denotes the 1-week basal insulin washout period during which participants switched to NPH and total
insulin dose was reduced by 20%. (e) Nine-point profiles of self-monitored blood glucose calibrated to plasma glucose, at baseline (week 0) and after
104 weeks of treatment. Hypoglycaemia data correspond to observed data for the safety analysis set comprising all subjects exposed to treatment.
Confirmed hypoglycaemic episodes included either episodes confirmed by self-monitored blood glucose corresponding to plasma glucose value
< 3.1 mmol/l or severe episodes requiring assistance. Episodes occurring between 00:01 and 05:59 h (both inclusive) were classified as nocturnal.
Glycaemic efficacy data are reported as the mean  standard error of the mean (SEM) for the extension trial set, comprising participants who
completed the core trial and entered the extension trial. Missing post-baseline data were imputed using the last-observation-carried-forward
approach. Baseline was defined as the time of randomization in the core trial.
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reported by 58% and 55% of subjects treated with degludec
and glargine, respectively. Overall confirmed hypoglycaemia
rates were similar between degludec and glargine when
considering the entire trial period [1.72 and 2.05 episodes/
patient-year; estimated rate ratio of 0.84 (95% CI 0.68–
1.04), P = 0.115] and maintenance period [1.80 and 2.21
episodes/patient-year; estimated rate ratio of 0.80 (95% CI
0.63–1.01), P = 0.063] (Fig. 1a and Table 1). Nocturnal
confirmed hypoglycaemia was significantly lower by 43%
with degludec at end of trial [0.27 vs. 0.46 episodes/
patient-year; estimated rate ratio of 0.57 (95% CI 0.40–
0.81), P = 0.002] and significantly lower by 53% in the
maintenance period [0.28 vs. 0.53 episodes/patient-year;
estimated rate ratio of 0.47 (95% CI 0.32–0.69), P < 0.001]
(Fig. 1b and Table 1). The rate of severe hypoglycaemia was
significantly lower with degludec than glargine when con-
sidering the entire trial period for the safety analysis set
[0.006 vs. 0.021 episodes/patient-year; estimated rate ratio
of 0.31 (95% CI 0.11–0.85), P = 0.023] (Table 1). The
results for overall confirmed, nocturnal confirmed and severe
hypoglycaemia in the extension trial set (Table 1) were
consistent with those observed for the safety analysis set.
At end of treatment, 81% of degludec-treated and 77% of
glargine-treated subjects reported an adverse event; 96% of
events were mild or moderate. The rate of adverse events
possibly or probably related to insulin was similar for both
degludec and glargine (0.19 events per patient-year). The
most frequently reported adverse events in both treatment
groups were nasopharyngitis, headache and diarrhoea. Seri-
ous adverse events were reported by 15.1 and 16.0% of
subjects in the degludec and glargine treatment groups,
respectively. The rate of serious adverse events was low; 0.15
(degludec) and 0.17 (glargine) events per patient-year. The
most frequently reported serious adverse events were cardiac
disorders (0.05 events per patient-year in each group). The
rate of serious adverse events judged to be possibly or
probably related to treatment by the investigator was the
same in both treatment groups (0.01 events per patient-year).
The rate of injection-site reactions was similar in the
degludec and glargine groups (0.07 and 0.08 events per
patient-year, respectively). Observed mean weight gain at
end of treatment was similar with degludec (2.7 kg) and
glargine (2.4 kg); estimated treatment difference of 0.37 kg
(95% CI 0.35 to 1.10), P = 0.31.
One death in each group, both considered unrelated to
treatment, was reported during the main trial [2]. Seven
additional deaths were reported in the extension trial: four in
the degludec group (small-cell lung cancer, pseudomembra-
nous colitis/large intestine perforation/multiple organ failure,
rectal cancer and death as the result of an unknown cause)
and three in the glargine group (motor vehicle accident,
myocardial infarction and non-treatment-emergent cardiac
arrest). Four of nine deaths were major adverse cardiovas-
cular events: death by unknown cause and sudden cardiac
death in the degludec group; cardiac arrest and myocardial
infarction in the glargine group. The rate of major adverse
cardiovascular events was 0.03 (degludec) and 0.01 (glar-
gine) events per patient-year (not significant). No clinically
relevant differences in other safety assessments were
observed between the treatment groups.
Immunogenicity of insulin degludec, assayed by deglu-
dec-specific antibodies (median = 0% bound/total radioac-
tivity) and antibodies cross-reacting between degludec and
human insulin (median = 0% bound/total radioactivity), was
low throughout treatment [2].
Efficacy
In the extension trial set, after 104 weeks of treatment, the
observed mean (SD) HbA1c decreased from 65  9 mmol/
mol (8.1  0.8%) at baseline to 53  10 mmol/mol (7.0 
0.9%) with degludec and from 66  9 mmol/mol
(8.2  0.8%) at baseline to 52  9 mmol/mol (6.9 
0.8%) with glargine, and there was no statistical difference
between treatments; estimated treatment difference of
1 mmol/mol (95% CI 1 to 3) [0.07% (95% CI 0.07 to
0.22), P = 0.339] (Fig. 1c). Similar results were obtained in
analyses of the full analysis set: estimated treatment differ-
ence of 1 mmol/mol (95% CI 0–3) [0.12% (95% CI 0.01
to 0.25), P = 0.078]. In the extension trial set, labora-
tory-measured fasting plasma glucose decreased rapidly in
the first 12 weeks and did not increase over the remainder of
the 52-week core trial (Fig. 1d). The fasting plasma glucose
increased abruptly during the 1-week basal insulin washout
period (occurring between the core and extension trial),
when participants switched to NPH and reduced their total
daily insulin dose by 20%. Observed mean (SD) fasting
plasma glucose decreased from 9.66  2.37 mmol/l at base-
line to 5.56  1.82 mmol/l at end of treatment with deglu-
dec, and from 9.53  2.36 mmol/l to 5.93  1.69 mmol/l
with glargine (Fig. 1d). These values remained above the
target fasting plasma glucose to which insulin was titrated.
The observed mean reduction in laboratory-measured fasting
plasma glucose was significantly greater with degludec
(4.17 mmol/l) than with glargine (3.56 mmol/l) [estimated
treatment difference 0.36 mmol/l (95% CI 0.67 to
0.05), P = 0.021] (Fig. 1d). Similar results were seen for
the full analysis set [estimated treatment difference
0.38 mmol/l (95% CI 0.70 to 0.06), P = 0.019]. The
9-point self-monitored blood glucose profiles were similar
at baseline and at end of treatment for both treatments in
the extension trial set (Fig. 1e) and the full analysis set (data
not shown), with no significant difference in prandial
increments.
Discussion
The 2-year exposure to insulin degludec or glargine in
previously insulin-naive patients with Type 2 diabetes
provided an opportunity to compare overall safety of
ª 2013 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 1301
Research article DIABETICMedicine
degludec with that of glargine, while evaluating long-term
glycaemic efficacy.
The principal findings of the 52-week, core trial [2],
namely that degludec provides improved glycaemic control
similar to glargine (similar HbA1c reduction with greater
reduction in fasting plasma glucose), using similar insulin
doses, with lower rates of nocturnal and severe hypoglyca-
emia and similar weight gain, were sustained for a full
104 weeks of treatment. Although rates of diurnal con-
firmed hypoglycaemia (confirmed hypoglycaemia occurring
between 06:00 and 00:00 h) were similar between treat-
ments, insulin degludec showed a consistently and signifi-
cantly lower rate of nocturnal hypoglycaemia as compared
with glargine, and this difference widened over the course of
2 years (P < 0.01). The lower rate of nocturnal hypoglyca-
emia can be attributed to the flat pharmacokinetic and
pharmacodynamic profile of insulin degludec combined with
the reduced variability within subjects between days and also
between subjects [5,6].
The degludec phase 3 programme was a global clinical
development programme, and the window of time for
defining nocturnal hypoglycaemia was chosen, taking into
consideration the variability of timing of meals around the
world to ensure that the period chosen was truly nocturnal
and not confounded by meal ingestion or use of bolus insulin
(relevant for trials in the degludec development programme
using basal–bolus insulin therapy). Thus, all analyses of
nocturnal hypoglycaemia in the clinical development pro-
gramme for insulin degludec were carried out according to
the definition set a priori for nocturnal hypoglycaemia—
hypoglycaemic episodes occurring between 00:01 and
05:59 h (both inclusive). The relevance of the (absolute)
Table 1 Hypoglycaemic episodes in the insulin degludec and insulin glargine groups
Safety analysis set, entire trial period
Insulin degludec once daily
(N = 766)
Insulin glargine once daily
(N = 257) Estimated rate
ratio; insulin
degludec/insulin




Episodes Raten % n %
Severe 6 0.8 7 0.006 7 2.7 8 0.021 0.31 (0.11–0.85) 0.023
Overall confirmed 444 58.0 2081 1.72 141 54.9 789 2.05 0.84 (0.68–1.04) 0.115
Nocturnal confirmed 158 20.6 325 0.27 61 23.7 176 0.46 0.57 (0.40–0.81) 0.002
Subjects in the safety analysis set with at least 16 weeks of exposure, maintenance period (16 weeks to end of treatment)
Insulin degludec once daily
(N = 685)
Insulin glargine once daily
(N = 226) Estimated rate
ratio; insulin
degludec/insulin




Episodes Raten % n %
Severe 6 0.9 7 0.007 5 2.2 6 0.019 0.42 (0.14–1.26) 0.122
Overall confirmed 389 56.8 1777 1.80 125 55.3 687 2.21 0.80 (0.63–1.01) 0.063
Nocturnal confirmed 138 20.1 274 0.28 55 24.3 164 0.53 0.47 (0.32–0.69) < 0.001
Extension trial set, entire trial period
Insulin degludec once daily
(N = 551)
Insulin glargine once daily
(N = 174) Estimated rate
ratio; insulin
degludec/insulin




Episodes Raten % n %
Severe 6 1.1 7 0.006 6 3.4 7 0.021 0.33 (0.12–0.96) 0.042
Overall confirmed 376 68.2 1903 1.74 120 69.0 701 2.06 0.83 (0.65–1.05) 0.121
Nocturnal confirmed 137 24.9 290 0.27 53 30.5 144 0.42 0.58 (0.39–0.86) 0.002
Hypoglycaemic episodes (severe, overall confirmed and nocturnal confirmed) occurring on or after the first day of exposure to treatment and
no later than 7 days after the last day of treatment with insulin degludec or insulin glargine are included for all exposed subjects in the safety
analysis set and for subjects completing the core trial that continued into the extension trial in the extension trial set. Hypoglycaemic episodes
occurring in subjects with at least 16 weeks of exposure to treatment (i.e. from week 16 onwards to the end of 104 weeks of treatment) are
included in the maintenance period.
*Statistical analysis based on the full analysis set comprising all randomized subjects.
†Statistical analysis based on the extension trial set.
N, subjects contributing to analysis; n, number of participants with hypoglycaemic episodes; Rate, episodes per patient-year of exposure;
%, proportion of participants with hypoglycaemic episodes.
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difference in hypoglycaemia rates between the two treat-
ments in this study is apparent when considering the clinical
impact. Only five patients with Type 2 diabetes need to be
treated for a year with insulin degludec to observe the benefit
of avoiding one nocturnal confirmed hypoglycaemic episode
compared with glargine as the treatment alternative—that is,
treating 100 patients for a year with insulin degludec would
result in 19 fewer episodes of nocturnal confirmed hypo-
glycaemia compared with insulin glargine treatment.
The sustained treatment benefits of degludec are important
to the management of diabetes, a chronic disease, and in
potentially lowering the risk of diabetic complications. As
hypoglycaemia and fear of hypoglycaemia are two of the
major barriers to optimizing glycaemic control [7,8], insulin
degludec appears to provide a significantly improved clinical
response in patients with Type 2 diabetes.
Abstract presentation
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Reduced nocturnal hypoglycaemia with insulin degludec as
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